Incorporated in 2008, Kronox Lab Sciences Ltd (KLSL) is engaged in the manufacturing of high purity fine and specialty chemicals, including inorganic chemicals, phosphates, and metallic chemicals. KLSL operates in the High Purity Specialty Fine Chemicals Business with a portfolio of about 185 products, which encompasses excipients and ingredients, high purity reagents, and pharmaceutical, nutraceutical, and food chemicals. The company manufactures high purity specialty fine chemicals for diverse industries, including pharmaceuticals, nutraceuticals, veterinary, food, and chemical analysis markets, offering a wide range of chemical products such as acetates, phosphates, and ultra-pure metallic salts.
Kronox Lab Sciences Limited was initially incorporated as `Kronox Lab Sciences Private Limited` on November 18, 2008. It subsequently converted into a Public Limited Company, receiving a fresh Certificate of Incorporation on June 11, 2019, from the Registrar of Companies, Ahmedabad, formally changing its name to `Kronox Lab Sciences Limited`.
The company operates through multiple manufacturing units with a strong focus on quality and compliance. Kronox Lab Sciences is a bulk manufacturer of high purity fine chemicals, meeting stringent industry standards such as IP, BP, EP, JP, USP, FCC, LR, AR, GR, and ACS. They also offer custom manufacturing specifications when required by customers.
Kronox Lab Sciences began its journey in 2009 by establishing its first manufacturing unit (Unit I) for High Purity Specialty Fine Chemicals. Unit I was expanded in 2011 to cater to the pharmaceutical and nutraceutical industries and later started manufacturing for the solar industry. In 2015, the company commenced operations at Unit II, adding new factory sheds and expanding its production capabilities, with manufacturing at Unit II beginning in 2019.
The company's High Purity Specialty Fine Chemicals are utilized in a variety of critical applications, including the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products. Kronox Lab Sciences offers a comprehensive range of over 185 products, including phosphates, sulphates, acetates, chlorides, citrates, nitrates, nitrites, carbonates, EDTA derivatives, hydroxides, succinates, gluconates, and other specialized chemicals.
Kronox Lab Sciences serves a broad customer base, supplying its products to clients in India and more than 20 countries worldwide. The company exports its specialty chemicals to international markets, including the United States, Argentina, Mexico, Australia, Egypt, Spain, Turkey, United Kingdom, Belgium, United Arab Emirates, China, among others, highlighting its strong global footprint.
The company has demonstrated a robust financial performance, characterized by consistent revenue and profit growth.
For the financial year ended March 2025:
- Net profit rose 19.30% to ₹25.47 crore, compared to ₹21.35 crore in FY 2024.
- Sales increased by 11.50% to ₹100.19 crore, up from ₹89.86 crore in FY 2024.
For the quarter ended March 2025:
- Net profit rose 7.48% to ₹6.32 crore, compared to ₹5.88 crore in the previous quarter ended March 2024.
- Sales increased by 17.81% to ₹26.13 crore, up from ₹22.18 crore in the previous quarter ended March 2024.
- Market Capitalization: ₹725.64 crore (as of 3rd July 2025)
- P/E (Price-to-Earnings) Ratio: 28.49
- 52-week High: ₹228.88
- 52-week Low: ₹132.05
- Revenue for FY 2025: ₹100.19 crore
- Net Profit for FY 2025: ₹25.47 crore
- Profit Growth: Delivered good profit growth of 24.3% CAGR over the last 5 years.
- Debt Status: The company is almost debt-free, indicating strong financial health.
- Return on Equity (ROE): Maintains a good ROE track record with a 3-Year ROE of 35.9%.
The Board of Directors of Kronox Lab Sciences, in its meeting held on May 22, 2025, recommended a final dividend of ₹0.5 per equity share (i.e., 5%), subject to shareholders' approval. The current dividend yield of Kronox Lab Sciences Ltd (KRONOX) is 0.26%.
Promoter Holding: Promoter holding in Kronox Lab Sciences Ltd increased to 74.21% as of March 2025, from 74.21% as of June 2024, indicating consistent promoter confidence.
Kronox Lab Sciences IPO initiated its bidding process from June 3, 2024, and concluded on June 5, 2024. The allotment for the IPO was finalized on Thursday, June 6, 2024. The shares were subsequently listed on both BSE and NSE on June 10, 2024, with the IPO price band set at ₹136 per share.
Kronox Lab Sciences Ltd (KRONOX) is classified under the Materials sector, specifically within the Specialty Chemicals sub-sector. The company operates in a competitive environment, with major competitors including Indokem, Sunshield Chemicals, Sadhana Nitro Chem, Vikram Thermo (India), Indo Borax & Chem., Stallion India Fluor, and Primo Chemicals.
- Company Secretary & Compliance Officer: Nikhil Goswami
- Registered Office: Block # 353 Village Ekalbara, Padra, Vadodara, Gujarat - 391440
- Phone: +91 26 6224 4077/88
Kronox Lab Sciences represents a growing and robust player in the specialty chemicals sector. Its strong focus on manufacturing high-purity chemicals and maintaining compliance with international standards has enabled it to establish itself as a reliable supplier to both domestic and international markets. The company's diverse product portfolio, spanning pharmaceutical, nutraceutical, and food-grade chemicals, combined with its debt-free status and consistent growth trajectory, makes it an attractive proposition for investors seeking exposure to the specialty chemicals sector.
